Adial Pharmaceuticals Inc ADIL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.54
- Day Range
- $2.40–2.90
- 52-Week Range
- $0.21–5.44
- Bid/Ask
- $2.65 / $3.00
- Shares Outstanding
- 2.19M
- Market Cap
- $6.02M
- Volume/Avg
- 202 / 458,253
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.adial.com
Valuation
|
Metric
|
ADIL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.21 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ADIL
|
|---|---|
Quick Ratio | 3.04 |
Current Ratio | 3.18 |
Interest Coverage | — |
Quick Ratio
ADIL
Profitability
|
Metric
|
ADIL
|
|---|---|
Return on Assets (Normalized) | −129.14% |
Return on Equity (Normalized) | −169.29% |
Return on Invested Capital (Normalized) | −173.09% |
Return on Assets
ADIL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Affymax Inc
AFFY
| — | Vhtkl | — | |||
| Athersys Inc
ATHXQ
| — | Jtz | — | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ystsfcv | Cmkwbnp | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zcznvxq | Ssfpqsf | $64B | |||
| UCB SA
UCBJF
| — | Xrgtw | $61B | |||
| UCB SA ADR
UCBJY
| — | Wlmk | $61B | |||
| argenx SE
ARGNF
| — | Whht | $56B | |||
| argenx SE ADR
ARGX
| Xfkctss | Ttfmk | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Tkjbxycs | Nnvpqkg | $38B | |||
| CSL Ltd
CMXHF
| — | Snnqqp | $36B |
United States